<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02060604</url>
  </required_header>
  <id_info>
    <org_study_id>NSAIDs_01</org_study_id>
    <nct_id>NCT02060604</nct_id>
  </id_info>
  <brief_title>Pilot Study of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration</brief_title>
  <official_title>A Randomised Controlled Trial of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Università degli Studi di Brescia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Università degli Studi di Brescia</source>
  <brief_summary>
    <textblock>
      The addition of an anti-inflammatory agent could be a valid option for controlling choroidal
      neovascularization, as simply inhibiting VEGF addresses neither the multifactorial
      pathogenesis of choroidal neovascularization nor the underlying cause of VEGF production.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mean change in study eye visual acuity as measured by the best-corrected ETDRS letter score</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>mean change in central macular thickness</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean number of intravitreal injections over the 12-month period</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse ocular events at 12 months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Wet Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Ketorolac + Ranibizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 monthly ranibizumab, then as needed plus ketorolac eyedrops TID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ranibizumab Alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 monthly ranibizumab, then as needed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac + Ranibizumab</intervention_name>
    <description>3 monthly ranibizumab, then as needed Ketorolac TID</description>
    <arm_group_label>Ketorolac + Ranibizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>3 monthly ranibizumab, then as needed</description>
    <arm_group_label>Ranibizumab Alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ability to provide written informed consent and comply with study assessments for the
             full duration of the study;

          2. age &gt;40 years;

          3. presence of treatment-naïve neovascular AMD with a visual acuity between 20/25 and
             20/200 on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart. Inclusion
             criteria for AMD were neovascularisation, fluid, or haemorrhage under the fovea.

        Exclusion Criteria:

          1. any previous intravitreal treatment;

          2. previous laser treatment in the study eye;

          3. myopia &gt;7 dioptres in the study eye;

          4. concurrent eye disease in the study eye that could compromise visual acuity (eg,
             diabetic retinopathy, advanced glaucoma);

          5. concurrent corneal epithelial disruption or any condition that would affect the
             ability of the cornea to heal;

          6. known sensitivity to any component of the formulations under investigation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Russo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Brescia, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luisa Delcassi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Brescia, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Semeraro, Professor</last_name>
    <role>Study Director</role>
    <affiliation>University of Brescia, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <state>BS</state>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2014</study_first_submitted>
  <study_first_submitted_qc>February 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2014</study_first_posted>
  <last_update_submitted>February 8, 2014</last_update_submitted>
  <last_update_submitted_qc>February 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Università degli Studi di Brescia</investigator_affiliation>
    <investigator_full_name>Andrea Russo</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>ketorolac</keyword>
  <keyword>NSAIDs</keyword>
  <keyword>wet macular degeneration</keyword>
  <keyword>choroidal neovascularization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

